Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV

Hepatology

Volumn 44, Issue 4, 2006, Pages 907-914

  Van Der Molen, Renate G ^a   Sprengers, Dave ^a   Biesta, Paula J ^a   Kusters, Johannes G ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA; ADEFOVIR; ADENINE; ANTIVIRUS AGENT; CYTOKINE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CELL COUNT; CELL FUNCTION; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD; BLOOD; BONE MARROW CELL; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; VIROLOGY;

ADENINE; ADULT; AGED; ALANINE TRANSAMINASE; ANTIGENS, CD; ANTIVIRAL AGENTS; CYTOKINES; DENDRITIC CELLS; DNA, VIRAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELOID CELLS; PHOSPHONIC ACIDS; VIRAL LOAD;

EID: 33750610311     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21340     Document Type: Article

References (32)

1. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-1956.
2. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-1683.
3. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
4. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. HEPATOLOGY 2000;32:1117-1124.
5. Maini MK, Boni C, Ogg GS, King AS, Reignat S, Lee CK, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999;117:1386-1396.
6. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-1280.
7. Marinos G, Torre F, Chokshi S, Hussain M, Clarke BE, Rowlands DJ, et al. Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. HEPATOLOGY 1995;22:1040-1049.
8. Van der Molen RG, Sprengers D, Binda RS, De Jong EC, Kusters JG, Kwekkeboom J, et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. HEPATOLOGY 2004;40: 738-746.
9. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. HEPATOLOGY 2005;41:771-778.
10. Gad M, Kristensen NN, Kury E, Claesson MH. Characterization of T-regulatory cells, induced by immature dendritic cells, which inhibit enteroantigen-reactive colitis-inducing T-cell responses in vitro and in vivo. Immunology 2004;113:499-508.
11. Beckebaum S, Cicinnati V, Dworacki G, Muller-Berghaus J, Stolz D, Harnaha J, et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 2002;104:138.
12. Arima S, Akbar SM, Michitaka K, Horiike N, Nuriya H, Kohara M, et al. Impaired function of antigen-presenting dendritic cells in patients with chronic hepatitis B: localization of HBV DNA and HBV RNA in blood DC by in situ hybridization. Int J Mol Med 2003;11:169-174.
13. Op den Brouw ML, Van Roosmalen MH, Kusters JG, Janssen HLA, Van der Molen RG. Functional impairment of mDC in chronic HBV patients: the role of HBV proteins. HEPATOLOGY 2005;42 (suppl 1):712A.
14. Untergasser A, Zedler U, Langenkamp A, Hosel M, Quasdorff M, Esser K, et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. HEPATOLOGY 2006;43:539-547.
15. Langenkamp A, Casorati G, Garavaglia C, Dellabona P, Lanzavecchia A, Sallusto F. T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur J Immunol 2002;32:2046-2054.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
17. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22: 696-699.
19. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000;38:2897-2901.
20. Chen MT, Billaud JN, Sallberg M, Guidotti LG, Chisari FV, Jones J, et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A 2004;101: 14913-14918.
21. Chen M, Sallberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005;79:3016-3027.
22. Loirat D, Mancini-Bourgine M, Abastado JP, Michel ML. HBsAg/ HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection. Int Immunol 2003;15:1125-1136.
23. Yoneyama H, Matsuno K, Zhang Y, Murai M, Itakura M, Ishikawa S, et al. Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease. J Exp Med 2001;193:35-49.
24. Kunitani H, Shimizu Y, Murata H, Higuchi K, Watanabe A. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J Hepatol 2002;36:734-741.
25. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-548.
26. McKenzie JL, Calder VL, Starling GC, Hart DN. Role of tumour necrosis factor-alpha in dendritic cell-mediated primary mixed leucocyte reactions. Bone Marrow Transplant 1995;15:163-171.
27. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146.
28. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004;202:96-105.
29. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology 2001;103:131-136.
30. Stoop JN, Van der Molen RG, Kuipers EJ, De Man RA, Kusters JG, Janssen HLA. Adefovir treatment of chronic hepatitis B decreases regulatory T cells and partially restores the antiviral immune response. HEPATOLOGY 2005;42(suppl 1):714A.
31. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975.
32. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. HEPATOLOGY 2001;33:963-971.